Advertisement

Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group

Published:March 17, 2022DOI:https://doi.org/10.1016/j.clgc.2022.03.008

      Abstract

      Introduction

      The therapeutic repertoire available for advanced renal cell carcinoma (RCC), including tyrosine kinase inhibitors (TKIs) and immunotherapy, required for molecular biomarkers for response.

      Patients and Methods

      This was a phase I to II trial on the combination of pazopanib with interferon-alpha (INF-2A) as first-line treatment for advanced RCC. The primary endpoint was recommended phase II dose (RP2D) and efficacy in terms of objective response rate (ORR, RECIST 1.1 criteria). Secondary endpoints included safety and a translational study of molecular biomarkers in serum and exosomes from peripheral blood samples at three-time points: baseline, 8 weeks of treatment, and progression of the disease.

      Results

      Between July 2011 and July 2017, 53 eligible patients were treated and followed up (I, n = 20; II, n = 33). Pazopanib 800 mg + INF-2A 3 MIUs showed a manageable safety profile; therefore, it was selected for dose expansion. Overall, grade 3/4 toxicities were reported in 24 (72.7%) patients. The ORR was 27.2%. The 12-month OS rate was 83.6% (median not reached), and after 30.9 months of follow-up, 24 (72.7%) patients were still alive. CCL2, IL8, TNF-α, and PD-L1 were significantly overexpressed after treatment initiation, while TGF-β1 and CCL5 were significantly decreased. TNF-α, endoglin, and PD-L1 expression are correlated with the response after treatment initiation.

      Conclusion

      The trial did not reach its pre-specified target ORR. However, OS was longer than expected with pazopanib monotherapy. Changes in the molecular profile suggest a crucial role of vascular remodeling and inflammatory-mediated immune cell infiltration in optimal response to pazopanib plus INF-2A.

      Keywords

      Abbreviations:

      ccRCC (Clear cell renal cell carcinoma), CI (Confidence intervals), CR (Complete response), DFS (Disease-free survival), DLT (Dose limiting toxicities), MTD (Maximum tolerated dose), PR (Partial response), RD (Recommended dose)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel RL
        • Miller KD
        • Jemal A.
        Cancer statistics, 2019. CA.
        Cancer J Clin. 2019; https://doi.org/10.3322/caac.21551
        • Papale M
        • Vocino G
        • Lucarelli G
        • et al.
        Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma.
        Oncotarget. 2017; https://doi.org/10.18632/oncotarget.16341
        • Fisher R
        • Gore M
        • Larkin J.
        Current and future systemic treatments for renal cell carcinoma.
        Semin Cancer Biol. 2013; https://doi.org/10.1016/j.semcancer.2012.06.004
        • Climent MA
        • Muñoz-Langa J
        • Basterretxea-Badiola L
        • Santander-Lobera C.
        Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma.
        Crit Rev Oncol Hematol. 2018; https://doi.org/10.1016/j.critrevonc.2017.11.009
        • Vachhani P
        • George S.
        VEGF inhibitors in renal cell carcinoma.
        Clin Adv Hematol Oncol. 2016; 14: 1016-1028
        • Howlader N
        • Noone N
        • Krapcho K
        • et al.
        SEER Cancer Statistics Review, 1975-2018.
        J Natl Cancer Inst. 2019; (http//seer.cancer.gov/csr/1975_2018/)
        • Escudier B
        • Pluzanska A
        • Koralewski P
        • et al.
        Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
        Lancet. 2007; https://doi.org/10.1016/S0140-6736(07)61904-7
        • Motzer RJ
        • Hutson TE
        • Tomczak P
        • et al.
        Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma.
        N Engl J Med. 2007; https://doi.org/10.1056/nejmoa065044
        • Sternberg CN
        • Davis ID
        • Mardiak J
        • et al.
        Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
        J Clin Oncol. 2010; https://doi.org/10.1200/JCO.2009.23.9764
        • Motzer RJ
        • Escudier B
        • Powles T
        • et al.
        Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
        Br J Cancer. 2018; https://doi.org/10.1038/s41416-018-0061-6
        • Motzer RJ
        • Tykodi SS
        • Escudier B
        • et al.
        Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).
        J Clin Oncol. 2020; https://doi.org/10.1200/jco.2020.38.6_suppl.617
        • Tannir NM
        • McDermott DF
        • Escudier B
        • et al.
        Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
        J Clin Oncol. 2020; https://doi.org/10.1200/jco.2020.38.6_suppl.609
        • Bracarda S
        • Porta C
        • Sabbatini R
        • Rivoltini L.
        Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS review.
        Crit Rev Oncol Hematol. 2019; https://doi.org/10.1016/j.critrevonc.2018.07.009
        • Powles T
        • Plimack ER
        • Soulières D
        • et al.
        Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2020; https://doi.org/10.1016/S1470-2045(20)30436-8
        • Motzer RJ
        • Penkov K
        • Haanen J
        • et al.
        Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
        N Engl J Med. 2019; 380: 1103-1115https://doi.org/10.1056/nejmoa1816047
        • Choueiri TK
        • Powles T
        • Burotto M
        • et al.
        Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
        N Engl J Med. 2021; 384: 829-841https://doi.org/10.1056/nejmoa2026982
        • You D
        • Song SH
        • Cho YM
        • et al.
        Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma.
        World J Urol. 2015; https://doi.org/10.1007/s00345-014-1295-4
        • Lee CH
        • Motzer RJ
        • Glen H
        • et al.
        Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.
        Br J Cancer. 2021; https://doi.org/10.1038/s41416-020-01092-0
        • Tran HT
        • Liu Y
        • Zurita AJ
        • et al.
        Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
        Lancet Oncol. 2012; https://doi.org/10.1016/S1470-2045(12)70241-3
        • Rini BI
        • Plimack ER
        • Stus V
        • et al.
        Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
        N Engl J Med. 2019; https://doi.org/10.1056/nejmoa1816714
        • Motzer RJ
        • Rini BI
        • McDermott DF
        • et al.
        Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
        Lancet Oncol. 2019; https://doi.org/10.1016/S1470-2045(19)30413-9
        • Motzer RJ
        • Choueiri TK
        • McDermott DF
        • et al.
        Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
        J Clin Oncol. 2020; https://doi.org/10.1200/jco.2020.38.15_suppl.5009
        • Harmon CS
        • Deprimo SE
        • Figlin RA
        • et al.
        Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
        Cancer Chemother Pharmacol. 2014; https://doi.org/10.1007/s00280-013-2333-4
        • Motzer RJ
        • Hutson TE
        • Hudes GR
        • et al.
        Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
        Cancer Chemother Pharmacol. 2014; https://doi.org/10.1007/s00280-014-2539-0
        • Motzer RJ
        • Robbins PB
        • Powles T
        • et al.
        Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
        Nat Med. 2020; https://doi.org/10.1038/s41591-020-1044-8
        • McDermott DF
        • Huseni MA
        • Atkins MB
        • et al.
        Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
        Nat Med. 2018; https://doi.org/10.1038/s41591-018-0053-3
        • Iacovelli R
        • Verzoni E
        • De Braud F
        • Procopio G.
        First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile.
        Cancer Biol Ther. 2014; https://doi.org/10.4161/cbt.27150
        • Beaumont JL
        • Salsman JM
        • Diaz J
        • et al.
        Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
        Cancer. 2016; https://doi.org/10.1002/cncr.29888
        • Amdahl J
        • Diaz J
        • Sharma A
        • et al.
        Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
        PLoS One. 2017; https://doi.org/10.1371/journal.pone.0175920
        • Villa G
        • Hernández-Pastor LJ.
        Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain.
        BMC Cancer. 2013; https://doi.org/10.1186/1471-2407-13-399
        • Unverzagt S
        • Moldenhauer I
        • Nothacker M
        • et al.
        Immunotherapy for metastatic renal cell carcinoma.
        Cochrane Database Syst Rev. 2017; https://doi.org/10.1002/14651858.CD011673.pub2
        • Rousseau B
        • Kempf E
        • Desamericq G
        • et al.
        First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
        Crit Rev Oncol Hematol. 2016; https://doi.org/10.1016/j.critrevonc.2016.08.012
        • van Horssen R
        • ten Hagen TLM
        • Eggermont AMM.
        TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility.
        Oncologist. 2006; https://doi.org/10.1634/theoncologist.11-4-397
        • Voss MH
        • Kuo F
        • Chen D
        • et al.
        Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy.
        J Clin Oncol. 2017; https://doi.org/10.1200/jco.2017.35.15_suppl.4523
        • Liu Y
        • Shang D.
        Transforming growth factor-β1 enhances proliferative and metastatic potential by up-regulating lymphoid enhancer-binding factor 1/integrin αMβ2 in human renal cell carcinoma.
        Mol Cell Biochem. 2020; https://doi.org/10.1007/s11010-019-03676-8
        • Yang Y
        • Zhai C
        • Chang Y
        • et al.
        High expression of chemokine CCL2 is associated with recurrence after surgery in clear-cell renal cell carcinoma.
        Urol Oncol Semin Orig Investig. 2016; https://doi.org/10.1016/j.urolonc.2015.11.026
        • Taubert H
        • Eckstein M
        • Epple E
        • et al.
        Immune Cell-associated protein expression helps to predict survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and optional adjuvant chemotherapy.
        Cells. 2021; https://doi.org/10.3390/cells10010159
        • Powles T
        • Bracarda S
        • Chen M
        • et al.
        Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.
        Eur J Cancer. 2015; https://doi.org/10.1016/j.ejca.2015.03.019